Ypsomed Holding AG is a Swiss multinational medical technology company specializing in the development and manufacturing of injection and infusion systems for self-medication. Headquartered in Burgdorf, Switzerland, it emerged in 2003 from the Disetronic Group and focuses primarily on diabetes care and biotechnology sectors. The company produces innovative devices such as insulin pens, autoinjectors, infusion pumps, and on-body delivery systems, enabling patients to manage chronic conditions independently and improve their quality of life. Under brands like mylife™ Diabetescare for direct-to-consumer sales via pharmacies and clinics, and Ypsomed Delivery Systems for business-to-business partnerships with pharmaceutical and biotech firms, it offers customized solutions for subcutaneous administration of liquid medications. Ypsomed operates a global network of manufacturing sites and subsidiaries, employing over 2,800 people as of 2025 with annual turnover exceeding 728 million Swiss Francs. As a key player in health technology, it supports treatments for diabetes, autoimmune diseases, obesity, and rare conditions, emphasizing reliability, innovation, and integration with digital health services.